Esin Şair

Dr. Esin Şair


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EŞEsin Şair
Esin Şair
OŞORHAN ŞAHİN
ORHAN ŞAHİN
AHAdnan Haşlak
Adnan Haşlak
ŞOŞeref Oray
Şeref Oray
Background: This study investigated an exploratory Combined Biomarker Score (CBS)—integrating the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score, Prognostic Nutritional Index (PNI), and lymph node ratio (LNR)—in resected ampullary adenocarcinoma, with methodological emphasis on censoring, score construction, collinearity, and internal validation. Methods: Data from 98 patients undergoing pancreaticoduodenectomy were analyzed retrospectively. The PNI was determined using the standard formula: (10 × albumin [g/dL]) + (0.005 × lymphocyte count [/mm3]), equivalent to albumin [g/L] + 5 × lymphocytes [×109/L]. Thirty-six-month cumulative/dynamic time-dependent ROC analysis with inverse-probability-of-censoring weighting was utilized to derive exploratory HALP, PNI, and LNR thresholds. Overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards regression. Spearman correlations, variance inflation factors, proportional-hazards diagnostics, alternative model specifications, apparent calibration, and 1000-resample full-procedure bootstrap validation were performed. Results: The mean PNI was 47.92 ± 6.36 (median 48.05, IQR 42.66–52.06). At 36 months, time-dependent AUCs were 0.579 for HALP, 0.567 for PNI, 0.512 for LNR, and 0.699 for the exploratory CBS. Optimized thresholds were established at HALP ≤ 26.784, PNI ≤ 46.20, and LNR ≥ 0.395. A high-risk CBS (2–3 adverse components) was observed in 27 of 98 patients and showed no statistically significant association with OS by log-rank testing (p = 0.142) or after adjustment for age and dichotomized stage (adjusted HR = 1.28, 95% CI: 0.58–2.80; p = 0.539). Age remained independently associated with OS (adjusted HR = 1.06 per year, p = 0.004). Model 4 (incorporating age, stage, and CBS) yielded an apparent Harrell C-index of 0.674 and a 36-month time-dependent AUC of 0.806; however, adding the CBS to age and stage did not significantly improve overall model fit (LR p = 0.543). Full-procedure bootstrap validation yielded an optimism-corrected C-index of 0.638. Conclusions: Evaluated via rigorous censoring-aware methodologies, the CBS currently serves as an exploratory framework rather than a validated clinical tool. While the score demonstrates moderate 36-month discrimination within this development cohort, it does not provide a statistically significant independent or incremental survival contribution beyond age and standard clinical variables. External validation and comprehensive clinicopathological adjustment are mandatory prior to any clinical translation.



1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
EŞEsin Şair
Esin Şair
MYMehmet Yazıcı
Mehmet Yazıcı
SASoykan Arıkan
Soykan Arıkan
MDMehmet Baki Dogan
Mehmet Baki Dogan

1 January 2026 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
BTBahaeddin Tapkan
Bahaeddin Tapkan
EŞEsin Şair
Esin Şair
MCMerve Cin
Merve Cin
SISaid İnCir
Said İnCir
SASoykan Arıkan
Soykan Arıkan